Covid-19, influenza A, influenza B, RSV-A, RSV-B: it is important that doctors are able to reliably determine the most common respiratory pathogens in one to two hours so that infected people can quickly receive personalised treatment. The test platform is usually set up close to the patient in hospitals, clinics or doctor's surgeries.
"The fully automated, point-of-care and high-throughput test platform is mobile and can therefore be used anywhere. Only one technician is required to operate it, rather than the five normally needed in a central laboratory to process up to 1,000 patient samples in an 8-hour shift," says Richard Lewis, founder and CEO of Fast MDx.
A separate handling system, based on the planar surface gantry EXCM-30, uses electric gripper EHPS-16 to pick up the filled microtiter plate and place it in the heat sealer, where it is sealed with a plastic film. The sealed plate is then placed in the RT block, which triggers the conversion of the RNA, if present, into complementary DNA (cDNA). In the final step, the PCR reaction takes place to determine whether the cDNA sequence of the pathogen of interest is present in any of the patient samples tested.
To avoid having to use an external pneumatic supply, the Fast MDx test platform uses the pressure and vacuum generator PGVA from Festo, which produces a pressure or vacuum of +/-0.5 bar. Only a 24-volt power supply is required to provide a pressure and vacuum solution with compressed air. The PGVA integrates a mini compressor, air filter unit, reservoir and electronic pressure and vacuum control in a very small space, providing a totally self-contained solution for liquid handling in laboratory automation.
"Thanks to the close cooperation between Fast MDx and Festo, we were able to build the first prototypes quickly and efficiently despite the extremely high complexity," says Richard Lewis, CEO of Fast MDx. "We were able to combine Fast MDx's extensive expertise in qPCR thermal cycling with Festo's proven 3D gantries, controllers and pipetting systems."